Lipoprotein apheresis influences monocyte subpopulations

Atheroscler Suppl. 2017 Nov:30:108-114. doi: 10.1016/j.atherosclerosissup.2017.05.027. Epub 2017 Jun 1.

Abstract

Background: Monocytes can be differentiated into subpopulations depending on their expression profile of CD14 and CD16. CD16-positive monocytes are associated with coronary artery disease. Up to now, no data exist about the effect of lipoprotein apheresis (LA) on the distribution of monocyte subpopulations.

Methods: 80 patients who underwent LA at the University Hospital Dresden were included in the study. 8 out of the 80 LA patients received LA for the first time at the time point of blood analysis. Six different methods of LA were used (H.E.L.P. n = 8; Liposorber D n = 10; LF n = 14; DALI n = 17; MONET n = 11; Therasorb® LDL n = 12). Blood samples were taken immediately before and after LA and analyzed for CD14 and CD16 expression on monocytes. A total of 42 patients with cardiovascular risk factors but no indication for LA served as control group.

Results: The composition of monocyte-population was analyzed in regard to the 3 subpopulations. After LA, an increase in classical monocytes (CD14++CD16-) (93.3% vs. 93.9%, p < 0.01) and a decrease in non-classical monocytes (CD14+CD16+) (1.5% vs 1.0%; p < 0.001) were observed. LA did not change the amount of intermediate monocytes (CD14++CD16+) (5.3% vs. 5.1%). Two methods (MONET and Therasorb® LDL) did not influence the distribution of monocyte subpopulations. Interestingly, patients with LDL-C above 2.5 mmol/l prior LA showed increased amounts of intermediate monocytes.

Conclusion: The distribution of monocyte populations is influenced by LA but depends on the distinct method of LA. Influences of LA were mainly observed in the content of classical and non-classical monocytes, whereas the intermediate monocyte population remained unaltered by LA.

Keywords: Lipoprotein apheresis; Monocytes; Subpopulations.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Blood Component Removal / adverse effects
  • Blood Component Removal / methods*
  • Case-Control Studies
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / immunology
  • Dyslipidemias / therapy*
  • Female
  • GPI-Linked Proteins / blood
  • Germany
  • Hospitals, University
  • Humans
  • Lipids / blood*
  • Lipopolysaccharide Receptors / blood
  • Male
  • Middle Aged
  • Monocytes / classification
  • Monocytes / immunology*
  • Phenotype
  • Receptors, IgG / blood
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • FCGR3B protein, human
  • GPI-Linked Proteins
  • Lipids
  • Lipopolysaccharide Receptors
  • Receptors, IgG